Ngo Hanh Thi Tuyet, Nguyen Duy Duc, Dang Minh-Xuan, Doan Thao Thi Phuong, Thai Truc Thanh
Department of Embryology - Pathology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Department of Pathology, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam.
J Hepatocell Carcinoma. 2025 Jun 11;12:1167-1175. doi: 10.2147/JHC.S524683. eCollection 2025.
Early recurrence of hepatocellular carcinoma (HCC) is not uniformly associated with microscopic vascular invasion (MVI). This study aims to identify the clinical and pathological factors associated with early recurrence in HCC patients without MVI.
A retrospective cohort study was conducted on 69 patients who underwent hepatectomy for HCC at the University Medical Center Ho Chi Minh city. All patients were microscopically confirmed as MVI-negative. Clinical and subclinical data, along with tumor recurrence within 24 months post-surgery were collected. Microscopic features of both tumor and non-tumor liver tissue were assessed using Hematoxylin-Eosin-stained slides.
The majority of patients were male (78.3%) and had cirrhosis (72.5%). The early recurrence rate was 31.9%, with most recurrences occurring between 6- and 18-month post-surgery. Independent factors for early tumor recurrence included preoperative treatment with Transarterial Chemoembolization (TACE) or Radiofrequency Ablation (RFA) (HR = 8.63, 95% CI = 1.45-51.38), tumor size > 5 cm (HR = 3.82, 95% CI = 1.17-12.42), and HCV infection (HR = 4.61, 95% CI = 1.41-15.1).
The pathogenesis and pattern of early tumor recurrence in MVI-negative HCC differ from that in MVI-positive cases. Identifying risk factors, such as HCV infection, tumor size, and preoperative locoregional therapy, may aid in optimizing treatment strategies and postoperative surveillance.
肝细胞癌(HCC)的早期复发并非均与微血管侵犯(MVI)相关。本研究旨在确定无MVI的HCC患者中与早期复发相关的临床和病理因素。
对胡志明市大学医学中心69例行肝癌肝切除术的患者进行回顾性队列研究。所有患者经显微镜检查均确认为MVI阴性。收集临床和亚临床数据以及术后24个月内的肿瘤复发情况。使用苏木精-伊红染色切片评估肿瘤和非肿瘤肝组织的微观特征。
大多数患者为男性(78.3%)且患有肝硬化(72.5%)。早期复发率为31.9%,大多数复发发生在术后6至18个月之间。早期肿瘤复发的独立因素包括术前经动脉化疗栓塞(TACE)或射频消融(RFA)治疗(HR = 8.63,95%CI = 1.45 - 51.38)、肿瘤大小>5 cm(HR = 3.82,95%CI = 1.17 - 12.42)以及HCV感染(HR = 4.61,95%CI = 1.41 - 15.1)。
MVI阴性HCC的早期肿瘤复发的发病机制和模式与MVI阳性病例不同。识别诸如HCV感染、肿瘤大小和术前局部区域治疗等危险因素,可能有助于优化治疗策略和术后监测。